Logo

Takeda to Merge with Syrrx

Feb 07, 2005

NEW YORK, Feb. 7 (GenomeWeb News) - Takeda Pharmaceutical, of Osaka, Japan, said today it has signed a deal to merge with Syrrx. The new company will be called the Takeda Group.

 

According to Takeda, the merger will combine Syrrx's high-throughput X-ray crystallography technology and R&D efforts with Takeda's own pipeline, and establish a discovery research presence for Takeda in the US. San Diego-based Syrrx will become part of Takeda's global discovery research network together with its existing discovery centers in Osaka and Tsukuba.

 

Terms of the deal, which is still subject to customary closing conditions, were not disclosed.

Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.